GB Sciences, Inc.

Equities

GBLX

US3615441090

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:31:25 16/07/2024 BST			5-day change	1st Jan Change
0.00835 ^USD	-4.02%		+18.31%	+31.25%

07-02	GB Sciences, Inc Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson?s Formulation With Endopure Life Sciences	CI
06-21	GB Sciences, Inc. and EndoPure Life Sciences, LLC Enter into A Non-Legally Binding Letter of Intent to Negotiate and Enter into A License Agreement	CI

GB Sciences, Inc. Announces Executive Changes

May 09, 2017 at 04:45 am

GB Sciences, Inc. announced the retirement and resignation, effective May 8, 2017, of its founder, Chairman and Chief Innovation Officer, Craig Ellins. John Poss, who replaced Mr. Ellins as CEO last year, now also serves as Chairman of the Board.

Latest news about GB Sciences, Inc.

GB Sciences, Inc Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson?s Formulation With Endopure Life Sciences	07-02	CI
GB Sciences, Inc. and EndoPure Life Sciences, LLC Enter into A Non-Legally Binding Letter of Intent to Negotiate and Enter into A License Agreement	06-21	CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-20	CI
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	14/07/23	CI
GB Sciences, Inc. Auditor Raises 'Going Concern' Doubt	13/07/23	CI
Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of Lethbridge	11/07/23	CI
GB Sciences, Inc. announced a financing transaction	29/06/23	CI
GB Sciences, Inc. Announces Executive Changes	14/04/23	CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	03/02/23	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	09/11/22	CI
Gb Sciences, Inc. Receives Positive Preclinical Results in an Interim Report from Its Study Using Preclinical Zebrafish Models of Stress At the National Research Council of Canada	24/10/22	CI
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	11/08/22	CI
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	30/06/22	CI
GB Sciences, Inc. Auditor Raises 'Going Concern' Doubt	29/06/22	CI
GB Sciences, Inc. announced a financing transaction	19/05/22	CI
Gb Sciences, Inc. Showcases Its Pharos™ Drug Discovery Platform At the 2Nd Alcor Drug Discovery Platform Summit	12/05/22	CI
GB Sciences, Inc. to Begin Dosage Study for its Novel Parkinson's Disease Formulations at the University of Lethbridge	12/04/22	CI
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research Article	29/03/22	CI
GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis	01/03/22	CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	11/02/22	CI
An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. for $8 million.	10/01/22	CI
Gb Sciences Reports Positive Results from Study of its Potential Treatment for Cytokine Release Syndrome	06/12/21	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	15/11/21	CI

Chart GB Sciences, Inc.

Duration

Period

More charts

Company Profile

GB Sciences, Inc. is a biopharmaceutical research and development company. The Company develops disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned subsidiary, GbS Global Biopharma, Inc. (GBSGB). The Company's primary focus is on preparing its lead program for the treatment of the motor symptoms of Parkinson's disease (PD) in a human clinical trial. Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB has a portfolio of intellectual property containing both plant-inspired formulations and its artificial intelligence (AI)-enabled drug discovery platform, as well as research contracts and various supplier arrangements. GBSGBs intellectual property covers a range of over 65 medical conditions, from which five drug development programs are in the preclinical stage of drug development.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GB SCIENCES, INC.	+31.25%	3.53M
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research